Azzad Asset Management Inc. ADV Acquires 16,296 Shares of Edwards Lifesciences Corporation $EW

Azzad Asset Management Inc. ADV boosted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 330.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 21,227 shares of the medical research company’s stock after purchasing an additional 16,296 shares during the quarter. Azzad Asset Management Inc. ADV’s holdings in Edwards Lifesciences were worth $1,651,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in EW. Rosenberg Matthew Hamilton bought a new stake in shares of Edwards Lifesciences during the second quarter valued at approximately $28,000. True Wealth Design LLC grew its stake in Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 259 shares in the last quarter. NewSquare Capital LLC increased its holdings in Edwards Lifesciences by 57.8% in the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 134 shares during the last quarter. Rakuten Securities Inc. lifted its stake in Edwards Lifesciences by 413.7% in the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after purchasing an additional 302 shares in the last quarter. Finally, Hantz Financial Services Inc. boosted its holdings in shares of Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 164 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,700 shares of the company’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total value of $650,419.00. Following the transaction, the chief financial officer owned 39,898 shares of the company’s stock, valued at $3,370,184.06. This represents a 16.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $85.66, for a total value of $971,384.40. Following the completion of the sale, the vice president owned 31,870 shares in the company, valued at approximately $2,729,984.20. The trade was a 26.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 43,804 shares of company stock worth $3,699,082. 0.34% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

EW has been the topic of a number of research analyst reports. Mizuho boosted their target price on Edwards Lifesciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. Raymond James Financial raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective on the stock in a report on Monday, November 3rd. BTIG Research restated a “buy” rating and issued a $103.00 price target (up previously from $100.00) on shares of Edwards Lifesciences in a research report on Thursday, December 4th. Robert W. Baird set a $90.00 price target on shares of Edwards Lifesciences in a research note on Monday, January 12th. Finally, TD Cowen raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Friday, January 9th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $96.77.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW opened at $78.71 on Monday. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89. The company has a market capitalization of $45.68 billion, a price-to-earnings ratio of 33.93, a PEG ratio of 3.03 and a beta of 0.94. The firm’s 50-day moving average is $84.15 and its 200 day moving average is $81.16.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.